Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Prognostic Immunohistochemistry for Ki-67 and OTP on Small Biopsies of Pulmonary Carcinoid Tumors
Jenkins, Sarah M. , Roden, Anja C. , Yi, Euhee S., Bois, Melanie C. , Maleszewski, Joseph J. , Aubry, Marie Christine, Naso, Julia , Yi, Eunhee S. , Lo, Ying‐Chun , Boland, Jennifer M.

Mayo Clinic

American Journal of Surgical Pathology | April 8, 2024 | Volume: 48 | Issue: 6 | Pages: 742-750

10.1097/pas.0000000000002227 | PMID 38584496 Get It

Prognostic stratification of pulmonary carcinoids into “typical” and “atypical” categories requires examination of large tissue volume. However, there is a need for tools that provide similar prognostic information on small biopsy samples. Ki-67 and OTP immunohistochemistry have shown promising prognostic value in studies of resected pulmonary carcinoids, but prognostic value when using biopsy/cytology specimens is unclear. Ki-67 immunohistochemistry was performed on small biopsy/cytology specimens from pulmonary carcinoid tumors (n=139), and labeling index was scored via automated image analysis of at least 500 cells. OTP immunohistochemistry was performed on 70 cases with sufficient tissue and scored as positive or negative (<20% tumor nuclei staining). Higher Ki-67 index was associated with worse disease-specific progression-free survival (ds-PFS), with 3% and 4% thresholds having similarly strong associations with ds-PFS ( P <0.001, hazard ratio ≥11). Three-year ds-PFS was 98% for patients with Ki-67 <3% and 89% for patients with Ki-67≥3% ( P =0.0006). The optimal Ki-67 threshold for prediction of typical versus atypical carcinoid histology on subsequent resection was 3.21 (AUC 0.68). Negative OTP staining approached significance with atypical carcinoid histology ( P =0.06) but not with ds-PFS ( P =0.24, hazard ratio=3.45), although sample size was limited. We propose that Ki-67 immunohistochemistry may contribute to risk stratification for carcinoid tumor patients based on small biopsy samples. Identification of a 3% hot-spot Ki-67 threshold as optimal for prediction of ds-PFS is notable as a 3% Ki-67 threshold is currently used for gastrointestinal neuroendocrine tumor stratification, allowing consideration of a unified classification system across organ systems.
Abstract CT205: Neoadjuvant (Z)-endoxifen in premenopausal ER+, HER2- breast cancer: Evaluation of the first pharmacokinetic cohort of the EVANGELINE trial
Fraser, Heather , Mina, Lida A. , Advani, Pooja , Leon‐Ferre, Roberto A. , Hunt, Katie N. , Buhrow, Sarah A. , Schellenberg, Matthew J. , Hawse, John R. , Goetz, Matthew P. , Suman, Vera J. , Fraser, Heather, Giridhar, Karthik V. , Batalini, Felipe , Jayaraman, Swaathi , Jakub, James W. , Cronin, Patricia A. , Piltin, Mara A. , Degnim, Amy C. , Ingle, James N. , Boughey, Judy C. , Reid, Joel M. , Quay, Steven C.

Mayo Clinic

Cancer Research | April 5, 2024 | Volume: 84 | Issue: 7_Supplement | Pages: CT205-CT205

10.1158/1538-7445.am2024-ct205 Get It

Abstract Background: Ovarian function suppression (OFS) combined with tamoxifen (TAM) or an aromatase inhibitor (AI) is standard for premenopausal (PM) ER+, HER2- breast cancer (BC). However, &gt; 40% PM patients (pts) are intolerant of OFS. For these pts, TAM is the only FDA approved option. In the neoadjuvant endocrine setting, pts with endocrine sensitive disease (ESD) (Ki-67 ≤ 10% at 4 weeks) have 5yr dDFS &gt; 97%; however, only 45% of TAM pts vs &gt;75% with AI+OFS achieve 4 wk ESD (Nitz JCO 2022). (Z)-endoxifen (ENDX) is a potent anti-estrogen superior to TAM and AI in xenograft models and with antitumor activity in endocrine-resistant postmenopausal pts. ENDX additionally targets protein kinase C beta 1 (PKCβ1) at concentrations &gt;500 ng/mL, resulting in AKT inhibition and apoptosis (Jayaraman npj Breast Cancer 2023). We hypothesize that ENDX dual targeting of ERα and PKCβ1 will obviate the need for OFS and be non-inferior to AI plus OFS for PM pts with ER+/HER2- BC. Methods: EVANGELINE (NCT05607004) is an ongoing phase 2 multicenter neoadjuvant study with pharmacokinetic (PK) run-in assessing ENDX in PM women with ER+/HER2- BC. The primary objective for the PK run-in is to identify a dose (40 or 80 mg/day) resulting in ENDX steady state concentrations (Css) of 500-1000 ng/mL (to target both ERα and PKCβ1) without significant toxicity. Following PK run-in, the randomized phase II goal is to assess whether the ESD rate with ENDX is non-inferior to exemestane plus goserelin. Women with ESD at wk4 continue treatment for 24 weeks followed by surgery. Here we report the results from the 40 mg/day PK run-in. Results: Seven PM women (6 White, 1 Asian) aged 28-51 (median 46) received ENDX 40 mg/day. Pt characteristics on study were: ER &gt; 90% (all pts), median Ki-67 = 13 (range 4-33%), cTstage (cT2: 6 pts, cT3: 1 pt), and tumor grade (G1: 1 pt, G2: 6 pts). The median ENDX 28 day Css (ng/mL) was 263.6 (range 180.3-376.6). One pt discontinued due to wk4 Ki-67 remaining &gt; 10%. The remaining 6 had ESD, with either wk4 Ki-67 remaining ≤ 10% (3 pts) or decreasing to ≤ 10% (3 pts) and after 24 wks underwent surgery with surgical Ki-67 ≤ 3% (range 0-3%). MRI central review (wk12 and wk24) demonstrated target lesion decreases in all pts with 1 CR, 1 PR and 4 SD (RECIST). Treatment related toxicities included grade 3 headache (n=1), grade 2 amenorrhea (n=1), and grade 2 hot flashes (n=1). The median (range) baseline estrone (n=5) was 54 pg/mL (19-114) with median (range) fold increase from baseline of 9.0 (1.3-23.2) at wk4 and 4.7 (0.4 - 25.9) at wk24. The median baseline estradiol level (n=5) was 29 pg/mL (19-209) with median fold increases from baseline of 17.9 (0.4-57.0) at wk4 and 8.1 (0.04 - 56.6) at wk24. Additional surgical and blood biomarker data will be presented at the meeting. Conclusions: ENDX (40 mg/day) exhibits promising antitumor activity for PM ER+/HER2- BC but with ENDX Css below target. Enrollment is ongoing to the 80 mg/day dose level. Citation Format: Matthew P. Goetz, Vera J. Suman, Heather Fraser, Lida Mina, Pooja Advani, Roberto Leon-Ferre, Karthik Giridhar, Felipe Batalini, Katie N. Hunt, Swaathi Jayaraman, James Jakub, Patricia Cronin, Mara Piltin, Amy Degnim, James N. Ingle, Judy C. Boughey, Sarah Buhrow, Joel Reid, Matthew Schellenberg, John Hawse, Steven Quay. Neoadjuvant (Z)-endoxifen in premenopausal ER+, HER2- breast cancer: Evaluation of the first pharmacokinetic cohort of the EVANGELINE trial [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl):Abstract nr CT205.
Abstract CT136: Phase Ib study of siltuximab and spartalizumab in advanced pancreatic cancer
Gbolahan, Olumide B., Coleman, Kathleen, Cao, Yichun , Kane, Sujata , Craven, Sarah, Greene, Emily R. , McDonald, Andrew , Shaib, Walid L. , Akce, Mehmet , Diab, Maria , El‐Rayes, Bassel F. , El-Rayes, Bassel F , Gbolahan, Olumide B , Alese, Olatunji B. , Coleman, Kathleen M., Horvat, Natalie K. , Wu, Christina , Switchenko, Jeffrey M. , Lesinski, Gregory B

Mayo Clinic

Cancer Research | April 5, 2024 | Volume: 84 | Issue: 7_Supplement | Pages: CT136-CT136

10.1158/1538-7445.am2024-ct136 Get It

Abstract Background: Pancreatic adenocarcinoma (PDAC) is an aggressive malignancy with dismal prognosis. Most patients present with advanced stages. Heightened levels of serum interleukin-6 (IL-6) are associated with carcinogenesis, immune suppression, and poor prognosis in PDAC. Preclinical data of dual inhibition of IL-6 and programmed death ligand-1 (PD-L1) facilitates CD8+ T-cell migration into pancreatic tumors and was effective in controlling tumor growth in syngeneic and genetically engineered PDAC mouse models. Siltuximab (Sil) is a chimeric monoclonal antibody which targets the IL-6 molecule specifically. Spartalizumab (Sparta) is a high-affinity ligand-blocking humanized IgG4 antibody against the PD-1 receptor. We developed a phase Ib/II trial to evaluate the safety, immunogenicity and preliminary antitumor activity of Sil and Sparta in metastatic PDAC (mPDAC). Methods: Patients (pts) with mPDAC who have progressed on at least one line of systemic chemotherapy were eligible for the trial. Other selected inclusion criteria were ≥18 years of age, ECOG PS 0-1 and measurable disease per RECIST v1.1. The phase Ib trial design is standard 3+3, with a primary endpoint of recommended phase II dose (RP2D). An additional 24 patients were planned for an expansion cohort. Sil was administered at escalating dose levels of 6 mg/kg (DL1) and 11 mg/kg (DL2), in combination with Sparta at 300 mg IV on day 1 of each 21-day cycle. Key secondary endpoints included overall response rate (ORR = CR + PR), progression-free survival (PFS) and overall survival (OS). Results: We enrolled 4 patients on DL1 and escalated to DL2/RP2D in the absence of a dose limiting toxicity (DLT). A total of 31 patients were subsequently treated at the RP2D (escalation + expansion). The median age was 68 years, 42% were male. Majority were White (63%) and 20% were Black. About 43% had head of pancreas primary tumors and 86% had liver involvement. The median number of lines of prior therapy was 3 (range 1-4). There was no objective response among the 4 patients on DL1; 1 had stable disease (SD) for 11 weeks as best response. 17 of 31 patients on RP2D had only a baseline assessment and came off study for progression of disease, prior to follow-up imaging assessment for response evaluation. Of the 14 RP2D patients with a follow-up assessment, ORR was 0% (3 were SD and 11 had progression of disease (PD) as best response), mPFS - 2.2 mos (95% CI: 1.9, 2.6), mOS - 5.5mos (95% CI: 2.8, 6.5). Treatment related adverse events (TRAEs) of any grade included fatigue (23%), anemia (18%), and increased liver enzymes (9.5%). There were no grade 4-5 TRAEs. Conclusions: The combination Sil/Sparta had an acceptable safety profile but did not elicit responses in advanced PDAC pts. Correlative studies using paired biopsies and blood are ongoing to determine how dual IL-6/PD-1 blockade impacts stromal and immune biomarkers in relationship to the clinical outcome measures. Funding and medications for the study were provided by Novartis and Recordati Rare Diseases Inc (NCT04191421) and NIH/NCI (R21CA266088). Citation Format: Olatunji B. Alese, Olumide Gbolahan, Kathleen M. Coleman, Yichun Cao, Sujata Kane, Sarah Craven, Emily Greene, Natalie Horvat, Andrew McDonald, Walid L. Shaib, Christina S. Wu, Mehmet Akce, Maria Diab, Jeffrey M. Switchenko, Gregory B. Lesinski, Bassel F. El-Rayes. Phase Ib study of siltuximab and spartalizumab in advanced pancreatic cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl):Abstract nr CT136.
Effect of Active Workstations on Neurocognitive Performance and Typing Skills: A Randomized Clinical Trial
Medina‐Inojosa, José R. , Ibarra, Miguel A. Gomez, Medina‐Inojosa, Betsy J. , Supervía, Marta , Jenkins, Sarah M. , Johnson, Lynne L. , Moscoso, Nathalie P Suárez , Bonikowske, Amanda R. , Somers, Virend K. , López-Jiménez, Francisco , Gomez Ibarra, Miguel A, Johnson, Lynne, Suarez, Nathalie P , Bonikowske, Amanda , Somers, Virend K. , Lopez-Jimenez, Francisco , Medina-Inojosa, José R , Medina-Inojosa, Betsy , Johnson, Lynne

Mayo Clinic

Journal of the American Heart Association | April 4, 2024 | Volume: 13 | Issue: 8 | Pages: No page available

10.1161/jaha.123.031228 | PMID 38572691 Get It

Background Extended sedentary behavior is a risk factor for chronic disease and mortality, even among those who exercise regularly. Given the time constraints of incorporating physical activity into daily schedules, and the high likelihood of sitting during office work, this environment may serve as a potentially feasible setting for interventions to reduce sedentary behavior. Methods and Results A randomized cross‐over clinical trial was conducted at an employee wellness center. Four office settings were evaluated on 4 consecutive days: stationary or sitting station on day 1 (referent), and 3 subsequent active workstations (standing, walking, or stepper) in randomized order. Neurocognitive function (Selective Attention, Grammatical Reasoning, Odd One Out, Object Reasoning, Visuospatial Intelligence, Limited‐Hold Memory, Paired Associates Learning, and Digit Span) and fine motor skills (typing speed and accuracy) were tested using validated tools. Average scores were compared among stations using linear regression with generalized estimating equations to adjust standard errors. Bonferroni method adjusted for multiple comparisons. Healthy subjects were enrolled (n=44), 28 (64%) women, mean±SD age 35±11 years, weight 75.5±17.1 kg, height 168.5±10.0 cm, and body mass index 26.5±5.2 kg/m 2 . When comparing active stations to sitting, neurocognitive test either improved or remained unchanged, while typing speed decreased without affecting typing errors. Overall results improved after day 1, suggesting habituation. We observed no major differences across active stations, except decrease in average typing speed 42.5 versus 39.7 words per minute with standing versus stepping ( P =0.003). Conclusions Active workstations improved cognitive performance, suggesting that these workstations can help decrease sedentary time without work performance impairment. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06240286.
Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer
Leon‐Ferre, Roberto A. , Jonas, Sarah Flora , Salgado, Roberto, Loi, Sherene , Jong, Vincent de, Carter, Jodi M. , Leung, Samuel , Riaz, Nazia , Chia, Stephen , Jules-Clément, Gérôme , Curigliano, Giuseppe , Linderholm, Barbro, Deurzen, Carolien H. M. van , Timmermans, Anne, Yazaki, Shu, Yoshida, Masayuki , Bataillon, Guillaume , Kok, Marleen , Group, International Immuno-Oncology Biomarker Working, Curigliano, Giuseppe , Loi, Sherene , Carter, Jodi , Salgado, Roberto , Nielsen, Torsten O. , Criscitiello, Carmen , Cockenpot, Vincent , Lambertini, Matteo , Suman, Vera J. , Linderholm, Barbro Kristina , Martens, John W.M. , Timmermans, A. Mieke, Shimoi, Tatsunori , Kim, Sung-Bae , Lee, Hee Jin , Dieci, Maria Vittoria , Vincent‐Salomon, Anne , André, Fabrice , Linn, Sabine C. , Goetz, Matthew P. , Michiels, Stefan , Group, International Immuno-Oncology Biomarker Working

Mayo Clinic

JAMA | April 2, 2024 | Volume: 331 | Issue: 13 | Pages: 1135

10.1001/jama.2024.3056 | PMID 38563834 Get It

Importance The association of tumor-infiltrating lymphocyte (TIL) abundance in breast cancer tissue with cancer recurrence and death in patients with early-stage triple-negative breast cancer (TNBC) who are not treated with adjuvant or neoadjuvant chemotherapy is unclear. Objective To study the association of TIL abundance in breast cancer tissue with survival among patients with early-stage TNBC who were treated with locoregional therapy but no chemotherapy. Design, Setting, and Participants Retrospective pooled analysis of individual patient-level data from 13 participating centers in North America (Rochester, Minnesota; Vancouver, British Columbia, Canada), Europe (Paris, Lyon, and Villejuif, France; Amsterdam and Rotterdam, the Netherlands; Milan, Padova, and Genova, Italy; Gothenburg, Sweden), and Asia (Tokyo, Japan; Seoul, Korea), including 1966 participants diagnosed with TNBC between 1979 and 2017 (with follow-up until September 27, 2021) who received treatment with surgery with or without radiotherapy but no adjuvant or neoadjuvant chemotherapy. Exposure TIL abundance in breast tissue from resected primary tumors. Main Outcomes and Measures The primary outcome was invasive disease-free survival [iDFS]. Secondary outcomes were recurrence-free survival [RFS], survival free of distant recurrence [distant RFS, DRFS], and overall survival. Associations were assessed using a multivariable Cox model stratified by participating center. Results This study included 1966 patients with TNBC (median age, 56 years [IQR, 39-71]; 55% had stage I TNBC). The median TIL level was 15% (IQR, 5%-40%). Four-hundred seventeen (21%) had a TIL level of 50% or more (median age, 41 years [IQR, 36-63]), and 1300 (66%) had a TIL level of less than 30% (median age, 59 years [IQR, 41-72]). Five-year DRFS for stage I TNBC was 94% (95% CI, 91%-96%) for patients with a TIL level of 50% or more, compared with 78% (95% CI, 75%-80%) for those with a TIL level of less than 30%; 5-year overall survival was 95% (95% CI, 92%-97%) for patients with a TIL level of 50% or more, compared with 82% (95% CI, 79%-84%) for those with a TIL level of less than 30%. At a median follow-up of 18 years, and after adjusting for age, tumor size, nodal status, histological grade, and receipt of radiotherapy, each 10% higher TIL increment was associated independently with improved iDFS (hazard ratio [HR], 0.92 [0.89-0.94]), RFS (HR, 0.90 [0.87-0.92]), DRFS (HR, 0.87 [0.84-0.90]), and overall survival (0.88 [0.85-0.91]) (likelihood ratio test, P &amp;lt; 10e-6). Conclusions and Relevance In patients with early-stage TNBC who did not undergo adjuvant or neoadjuvant chemotherapy, breast cancer tissue with a higher abundance of TIL levels was associated with significantly better survival. These results suggest that breast tissue TIL abundance is a prognostic factor for patients with early-stage TNBC.
Frailty and Metabolic Vulnerability in Heart Failure: A Community Cohort Study
Kumar, Sant , Conners, Katherine M. , Shearer, Joseph J. , Joo, Jungnam , Turecamo, Sarah , Sampson, Maureen , Wolska, Anna , Remaley, Alan T. , Connelly, Margery A. , Otvos, James D. , Larson, Nicholas B. , Roger, Véronique L. , Bielinski, Suzette , Roger, Veronique L , Larson, Nicholas B , Kumar, Sant J , Bielinski, Suzette J.

Mayo Clinic

Journal of the American Heart Association | March 27, 2024 | Volume: 13 | Issue: 8 | Pages: No page available

10.1161/jaha.123.031616 | PMID 38533960 Get It

Background Frailty is common in heart failure (HF) and is associated with death but not routinely captured clinically. Frailty is linked with inflammation and malnutrition, which can be assessed by a novel plasma multimarker score: the metabolic vulnerability index (MVX). We sought to evaluate the associations between frailty and MVX and their prognostic impact. Methods and Results In an HF community cohort (2003–2012), we measured frailty as a proportion of deficits present out of 32 physical limitations and comorbidities, MVX by nuclear magnetic resonance spectroscopy, and collected extensive longitudinal clinical data. Patients were categorized by frailty score (≤0.14, >0.14 and ≤0.27, >0.27) and MVX score (≤50, >50 and ≤60, >60 and ≤70, >70). Cox models estimated associations of frailty and MVX with death, adjusted for Meta‐Analysis Global Group in Chronic Heart Failure (MAGGIC) score and NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide). Uno's C‐statistic measured the incremental value of MVX beyond frailty and clinical factors. Weibull's accelerated failure time regression assessed whether MVX mediated the association between frailty and death. We studied 985 patients (median age, 77; 48% women). Frailty and MVX were weakly correlated (Spearman's ρ=0.21). The highest frailty group experienced an increased rate of death, independent of MVX, MAGGIC score, and NT‐proBNP (hazard ratio, 3.3 [95% CI, 2.5–4.2]). Frailty improved Uno's c‐statistic beyond MAGGIC score and NT‐proBNP (0.69–0.73). MVX only mediated 3.3% and 4.5% of the association between high and medium frailty groups and death, respectively. Conclusions In this HF cohort, frailty and MVX are weakly correlated. Both independently contribute to stratifying the risk of death, suggesting that they capture distinct domains of vulnerability in HF.
International Prognostic Score for Nodular Lymphocyte–Predominant Hodgkin Lymphoma
Binkley, Michael S. , Flerlage, Jamie E. , Savage, Kerry J. , Akhtar, Saad , Steiner, Raphaël , Zhang, Xiaoyin , Dickinson, Michael , Major, Ajay , Hendrickson, Peter G. , Hopkins, David , Ng, Andrea K. , Casulo, Carla , Baron, Jonathan , Roberts, Kenneth B. , Alkendi, Jalila , Balogh, Alex, Torka, Pallawi , Specht, Lena , Silva, Ravi De , Pickard, Keir , Henry, M M , Smith, Christine M. , Brady, J.L. , Brennan, Bernadette , Сенченко, М. А. , Reeves, Marie, Terezakis, Stephanie , Fergusson, Paige, Hawkes, Eliza A. , Lee, Denise , Barraclough, Allison , Cheah, Chan Y. , Ku, Matthew , Mutsando, Howard , Gilbertson, Michael , Marconi, Tamara , Viiala, Nicholas , Hoppe, Richard T. , Borchmann, Peter , Fuchs, Michael , Hartmann, Sylvia , Eich, Hans Theodor, Skinnider, Brian, Milgrom, Sarah A. , Alomari, Mohammed H., Advani, Ranjana H. , Metzger, Monika L. , Wirth, Andrew, Smith, Sonali M. , Koenig, Julie L. , Sakthivel, Ku G., Gao, Sarah , Rahbi, Nasser Al, Sridhar, Akshay , Shah, Nimish , Osborne, Wendy , Chang, Isabela , Miall, Fiona , Mikhaeel, G., Penn, Anthony, Pepa, Roberta Della , Opat, Stephen , Tedjaseputra, Aditya , Palese, Monica , Kelly, Kara M. , Binkley, Michael Sargent , Major, Ajay , Hopkins, David , Ng, Andrea , Casulo, Carla , Baron, Jonathan , Roberts, Kenneth B , Al Kendi, Jalila , Ricardi, Umberto , Torka, Pallawi , Specht, Lena , De Silva, Ravindu , Pickard, Keir , Blazin, Lindsay J , Smith, Christine M , Brady, Jessica , Senchenko, Maria Anatolevna , Hoppe, Bradford S , Terezakis, Stephanie A , Hawkes, Eliza , Doo, Nicole Wong , Barraclough, Allison , Cheah, Chan Yoon , Ku, Matthew , Hamad, Nada , Gilbertson, Michael , Marconi, Tamara , Maurer, Matthew , Eichenauer, Dennis A , Hoppe, Richard T , Savage, Kerry J , Advani, Ranjana H , Opat, Stephen , Dickinson, Michael , Flerlage, Jamie E , Prica, Anca A. , Casulo, Carla , Blazin, Lindsay , Henry, Michael, Halperin, Daniel M. , Hoppe, Bradford S. , Talaulikar, Dipti , Picardi, Marco , Kirova, Youlia , Doo, Nicole Wong , Hamad, Nada , Maurer, Matthew J. , Eichenauer, Dennis A. , Hodgson, David C. , Rauf, M. Shahzad , Maghfoor, Irfan , Pinnix, Chelsea C. , Vega, Francisco , Alomari, Mohammed, Collins, Graham P. , Tsang, Richard , Kelsey, Chris R. , McKay, Pamela , Constine, Louis S , Plastaras, John Peter , Levis, Mario , Sridhar, Akshay, Volchkov, Egor Vasilevich , Northend, Michael , Salvaris, Ross , Shankar, Ananth , Natkunam, Yasodha

Mayo Clinic

Journal of Clinical Oncology | March 26, 2024 | Volume: 42 | Issue: 19 | Pages: 2271-2280

10.1200/jco.23.01655 | PMID 38531001 Get It

PURPOSE Nodular lymphocyte–predominant Hodgkin lymphoma (NLPHL) is a rare cancer, and large international cooperative efforts are needed to evaluate the significance of clinical risk factors and immunoarchitectural patterns (IAPs) for all stages of pediatric and adult patients with NLPHL. METHODS Thirty-eight institutions participated in the Global nLPHL One Working Group retrospective study of NLPHL cases from 1992 to 2021. We measured progression-free survival (PFS), overall survival (OS), transformation rate, and lymphoma-specific death rate. We performed uni- and multivariable (MVA) Cox regression stratified by management to select factors for the lymphocyte-predominant international prognostic score (LP-IPS) validated by five-fold cross-validation. RESULTS We identified 2,243 patients with a median age of 37 years (IQR, 23-51). The median follow-up was 6.3 years (IQR, 3.4-10.8). Most had stage I to II (72.9%) and few B symptoms (9.9%) or splenic involvement (5.4%). IAP was scored for 916 (40.8%). Frontline management included chemotherapy alone (32.4%), combined modality therapy (30.5%), radiotherapy alone (24.0%), observation after excision (4.6%), rituximab alone (4.0%), active surveillance (3.4%), and rituximab and radiotherapy (1.1%). The PFS, OS, transformation, and lymphoma-specific death rates at 10 years were 70.8%, 91.6%, 4.8%, and 3.3%, respectively. On MVA, IAPs were not associated with PFS or OS, but IAP E had higher risk of transformation (hazard ratio [HR], 1.81; P < .05). We developed the LP-IPS with 1 point each for age ≥45 years, stage III-IV, hemoglobin <10.5 g/dL, and splenic involvement. Increasing LP-IPS was significantly associated with worse PFS (HR, 1.52) and OS (HR, 2.31) and increased risk of lymphoma-specific death (HR, 2.63) and transformation (HR, 1.41). CONCLUSION In this comprehensive study of all ages of patients with NLPHL, we develop the LP-IPS to identify high-risk patients and inform upcoming prospective clinical trials evaluating de-escalation of therapy for patients with low LP-IPS scores (<2).
A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies
Kalogera, Eleftheria , Nevala, Wendy K. , Finnes, Heidi D. , Suman, Vera J. , Schimke, Jill M. , Strand, Carrie , Kottschade, Lisa A. , Kudgus, Rachel A. , Buhrow, Sarah A. , Becher, Laura , Geng, Liyi , Grudem, Megan E. , Jatoi, Aminah , Klampe, Carolyn M., Hendrickson, Andrea E. Wahner , Weroha, S. John , Yan, Yiyi , Block, Matthew S. , Strand, Carrie A , Elsbernd, Laura R. , Glaser, Gretchen , Grudem, Megan E , Jatoi, Aminah , Klampe, Carolyn M , Kumar, Amanika , Langstraat, Carrie L , McWilliams, Robert R , Wahner Hendrickson, Andrea E , Weroha, S John , Yan, Yiyi , Reid, Joel M , Markovic, Svetomir , Block, Matthew S , Suman, Vera , Glaser, Gretchen , Kumar, Amanika , Langstraat, Carrie , McWilliams, Robert R. , Reid, Joel M. , Markovic, Svetomir N.

Mayo Clinic

Clinical Cancer Research | March 26, 2024 | Volume: 30 | Issue: 12 | Pages: 2623-2635

10.1158/1078-0432.ccr-23-3196 | PMID 38530846 Get It

Abstract Purpose: AB160 is a 160-nm nano-immunoconjugate consisting of nab-paclitaxel (ABX) nanoparticles noncovalently coated with bevacizumab (BEV) for targeted delivery into tissues expressing high levels of VEGF. Preclinical data showed that AB160 resulted in greater tumor targeting and tumor inhibition compared with sequential treatment with ABX then BEV. Given individual drug activity, we investigated the safety and toxicity of AB160 in patients with gynecologic cancers. Patients and Methods: A 3+3 phase I trial was conducted with three potential dose levels in patients with previously treated endometrial, cervical, and platinum-resistant ovarian cancer to ascertain the recommended phase II dose (RP2D). AB160 was administered intravenously on days 1, 8, and 15 of a 28-day cycle (ABX 75–175 mg/m2, BEV 30–70 mg/m2). Pharmacokinetic analyses were performed. Results: No dose-limiting toxicities (DLT) were seen among the three dose levels tested. Grade 3/4 toxicities included neutropenia, thromboembolic events, and leukopenia. DL2 (ABX 150 mg/m2, BEV 60 mg/m2) was chosen as the RP2D. Seven of the 19 patients with measurable disease (36.8%) had confirmed partial responses (95% confidence interval, 16.3%–61.6%). Pharmacokinetic analyses demonstrated that AB160 allowed 50% higher paclitaxel dosing and that paclitaxel clearance mirrored that of therapeutic antibodies. Conclusions: The safety profile and clinical activity of AB160 supports further clinical testing in patients with gynecologic cancers; the RP2D is DL2 (ABX 150 mg/m2, BEV 60 mg/m2).
NAB2::STAT6 fusions and genome‐wide DNA methylation profiling: Predictors of patient outcomes in meningeal solitary fibrous tumors
Eschbacher, Kathryn L. , Tran, Quynh T. , Moskalev, Evgeny A. , Jenkins, Sarah M. , Fritchie, Karen , Stoehr, Robert , Caron, Alissa, Link, Michael J., Brown, Paul D. , Guajardo, Andrew, Wu, Ashley, Louis, David N. , Kaplan, Alexander , Ferrarese, Fabio, Raleigh, David R. , Nguyen, Minh , Gross, John , Vega, Jose Velazquez, Haller, Florian , Louis, David N , Giannini, Caterina , Link, Michael J. , Brat, Daniel J. , Santagata, Sandro , Brastianos, Priscilla K. , Alexander, Brian M. , Rossi, Sabrina , Vega, José E. Velázquez , Rodríguez, Fausto J. , Perry, Arie , Martinez‐Lage, Maria , Orr, Brent A. , Giannini, Caterina

Mayo Clinic

Brain Pathology | March 25, 2024 | Volume: 34 | Issue: 6 | Pages: No page available

10.1111/bpa.13256 | PMID 38523251 Get It

AbstractMeningeal solitary fibrous tumors (SFT) are rare and have a high frequency of local recurrence and distant metastasis. In a cohort of 126 patients (57 female, 69 male; mean age at surgery 53.0 years) with pathologically confirmed meningeal SFTs with extended clinical follow‐up (median 9.9 years; range 15 days–43 years), we performed extensive molecular characterization including genome‐wide DNA methylation profiling (n = 80) and targeted TERT promoter mutation testing (n = 98). Associations were examined with NAB2::STAT6 fusion status (n = 101 cases; 51 = ex5‐7::ex16‐17, 26 = ex4::ex2‐3; 12 = ex2‐3::exANY/other and 12 = no fusion) and placed in the context of 2021 Central Nervous System (CNS) WHO grade. NAB2::STAT6 fusion breakpoints (fusion type) were significantly associated with metastasis‐free survival (MFS) (p = 0.03) and, on multivariate analysis, disease‐specific survival (DSS) when adjusting for CNS WHO grade (p = 0.03). DNA methylation profiling revealed three distinct clusters: Cluster 1 (n = 38), Cluster 2 (n = 22), and Cluster 3 (n = 20). Methylation clusters were significantly associated with fusion type (p < 0.001), with Cluster 2 harboring ex4::ex2‐3 fusion in 16 (of 20; 80.0%), nearly all TERT promoter mutations (7 of 8; 87.5%), and predominantly an “SFT” histologic phenotype (15 of 22; 68.2%). Clusters 1 and 3 were less distinct, both dominated by tumors having ex5‐7::ex16‐17 fusion (respectively, 25 of 33; 75.8%, and 12 of 18; 66.7%) and with variable histological phenotypes. Methylation clusters were significantly associated with MFS (p = 0.027), but not overall survival (OS). In summary, NAB2::STAT6 fusion type was significantly associated with MFS and DSS, suggesting that tumors with an ex5::ex16‐17 fusion may have inferior patient outcomes. Methylation clusters were significantly associated with fusion type, TERT promoter mutation status, histologic phenotype, and MFS.
Abstract 1503: Melanoma-derived lymphatic extracellular vesicles suppress dendritic cell differentiation and maturation in the sentinel lymph node
Nevala, Wendy K. , Guo, Ray, Leontovich, Alexey A. , Moore, Raymond M. , Atherton, Chathu L., Geng, Liyi, McLaughlin, Sarah A. , Suman, Shankar , Jakub, James W. , Johnson, Jeffrey , Markovic, Svetomir N.

Mayo Clinic

Cancer Research | March 22, 2024 | Volume: 84 | Issue: 6_Supplement | Pages: 1503-1503

10.1158/1538-7445.am2024-1503 Get It

Abstract Spread to regional lymph nodes is the most common site of metastasis from melanoma and almost all solid tumors. Lymphatic metastases begin in the first lymph nodes draining from the primary tumor, i.e., the sentinel lymph nodes (SLN), preceded by the development of the premetastatic niche (PMN) initiated by primary cutaneous melanoma. Melanoma mediators are known to play a critical role in developing the PMN through the immune subversion in SLN. The DCs are a vital component of LN immunity that directly relates to eliciting T-cell functions. Our multiplex immunofluorescence (MxIF) analysis of SLNs indicates significantly decreased levels of DCs and cytotoxic-T cells in both core and interface areas of tumors in recurred patients treated with immunotherapy compared to non-recurred melanoma patients. The goal of this study is to determine whether the lymphatic extracellular vesicles (L-EVs) of melanoma patients regulate DC tolerization in SLN in order to stimulate the development of PMN. To identify whether L-EVs stimulate DC suppression, we extracted L-EVs from the lymphatic fluid of patients with melanoma downstream of primary cutaneous melanomas, compared it with controls (non-malignant post-operative fluid collected from the lymph node dissection field, and evaluated their effect on DC maturation by challenging these L-EVs in monocytic (CD14+) and hematopoietic stem cells (CD34+) cells. We found that L-EVs derived from melanoma patients suppress differentiation of CD11c+HLA-DR+ DCs and their maturation (defined by CD83 and CD86) compared to control L-EVs in CD14+ based DC maturation assay. We also found a reduction of conventional type 1 DC (cDC1) in CD34+-based DC maturation assay those challenged with patients’ L-EVs compared to control. To understand the mechanism of DC suppression in patients' L-EVs, we also conducted a total RNA sequencing analysis of subsets of DCs from maturation experiments to evaluate differently regulated transcriptomic profiles. The gene ontology analysis indicates that patient-derived L-EVs interfere with tRNA processing, oncostatin M & IL-10 signaling, and other immunoregulatory pathways to alter the hematopoietic cell lineage pathways in the DC maturation. Furthermore, the proteomic analysis of L-EVs also indicated several differentially regulated cargo-identified proteins in patient L-EVs, which are associated with immunomodulation, including regulation of DC function compared to control L-EVs. In conclusion, our study revealed that the patient's L-EVs carry differential proteomic cargoes secreted by cutaneous melanoma, which may be involved in regulating DC differentiation and maturation to diminish their functions and support the developing PMN in SLN. Citation Format: Shankar Suman, Wendy K. Nevala, James W. Jakub, Ray Guo, Alexey A. Leontovich, Raymond M. Moore, Chathu L. Atherton, Liyi Geng, Jeffrey E. Johnson, Sarah A. McLaughlin, Svetomir N. Markovic. Melanoma-derived lymphatic extracellular vesicles suppress dendritic cell differentiation and maturation in the sentinel lymph node [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1503.